問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital

Division of General Surgery

Division of Hematology & Oncology

更新時間：2024-02-21

黃怡菁
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

39Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

黃怡菁

List

50Cases

2026-06-01 - 2029-12-31

Phase II

Not yet recruiting
AN INTERVENTIONAL, OPEN-LABEL, PHASE 2 STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY OR IN COMBINATION IN ADULT PARTICIPANTS WITH EARLY-STAGE RESECTABLE OR LOCALLY ADVANCED UNRESECTABLE NON-SMALL CELL LUNG CANCER

  • Condition/Disease

    Non-Small-Cell Lung

  • Test Drug

    注射劑 注射劑 注射劑 注射劑

Participate Sites
5Sites

Not yet recruiting1Sites

2025-08-18 - 2030-06-30

Phase I/II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
4Sites

Recruiting4Sites

2026-01-15 - 2031-03-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Not yet recruiting6Sites

2026-03-04 - 2034-03-11

Phase II/III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Not yet recruiting5Sites

Recruiting1Sites

2026-08-31 - 2032-05-31

Phase I/II

Not yet recruiting
A Phase 1b/2, Multicenter, Open-label, Dose Regimen Determination and Dose Expansion Trial to Evaluate the Safety, Tolerability, Anti-tumor Activity, and an Optimal Dose Regimen of Patritumab Deruxtecan (HER3-DXd) With Trastuzumab Deruxtecan (T-DXd) in Participants With Hormone Receptor Positive, HER2-low or HER2-ultralow, Unresectable or Metastatic Breast Cancer (HERTHENA-Breast02)

  • Condition/Disease

    Hormone Receptor Positive , HER2-low or HER2-ultralow , Unresectable or Metastatic Breast Cancer

  • Test Drug

    注射用凍晶粉末

Participate Sites
5Sites

Not yet recruiting5Sites

2025-04-25 - 2029-02-28

Phase I/II

Active
An Open-label, Multi-center, Phase I/II Study of ECI830 as a Single Agent and in Combination With Ribociclib and Endocrine Therapy in Patients With Advanced Hormone Receptor Positive, HER2-negative Breast Cancer and Advanced Solid Tumors

  • Condition/Disease

    Advanced HR+/HER2- Breast Cancer

  • Test Drug

    膠囊劑

Participate Sites
1Sites

Recruiting1Sites

2025-07-01 - 2035-12-31

Phase III

Active
An Open-label, Randomized, Phase 3 Study to Evaluate Patritumab Deruxtecan Monotherapy Versus Treatment of Physician's Choice in Hormone Receptor-positive, HER2-negative Unresectable Locally Advanced or Metastatic Breast Cancer (HERTHENA-Breast04).

  • Condition/Disease

    Breast Neoplasms

  • Test Drug

    注射劑

Participate Sites
7Sites

Recruiting7Sites

2025-03-01 - 2032-12-31

Phase III

Active
A Phase 3, Randomized, Open-label Study Comparing Efficacy and Safety of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as a Monotherapy and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Expressing PD-L1 at CPS Less Than 10 (TroFuse-011)

  • Condition/Disease

    Triple Negative Breast Neoplasms

  • Test Drug

    注射用凍晶粉末 注射劑

Participate Sites
5Sites

Recruiting5Sites

2025-07-15 - 2030-12-31

Phase II

Active
A Multicenter, Open-label, Phase 2 Basket Study of MK-5684 in Participants With Selected Solid Tumors (OMAHA-015)

  • Condition/Disease

    Malignant Neoplasm

  • Test Drug

    錠劑 錠劑 注射劑 錠劑 注射劑 錠劑

Participate Sites
3Sites

Recruiting3Sites

2025-08-01 - 2030-12-31

Phase I

Active
A Phase I Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Clinical Activity of RO7673396 as a Single Agent and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors Harboring RAS Mutation(s)

  • Condition/Disease

    Neoplasms

  • Test Drug

    錠劑

Participate Sites
2Sites

Recruiting2Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB